Investigator brochures that investigators actually use

The Investigator Brochure (IB) is the working reference for every investigator in a clinical program: the compilation of clinical and non-clinical data that lets a site understand the product, dose rationale, and risks well enough to run the trial safely. ICH GCP defines its content, but the difference between a compliant IB and a good one is whether a busy investigator can find what matters, and whether the safety sections hold up when they are needed most.

EvySaif writes and updates IBs for drugs and biologics across development stages, from first-in-human documents built largely on non-clinical data to late-stage IBs synthesizing thousands of patient exposures. Our clinician writers structure the document to ICH GCP content expectations while writing the summaries an investigator can act on, and we treat the reference safety information with the care its regulatory function demands.

What makes the IB harder than it looks

• The reference safety information (RSI). The RSI section is used to determine whether a serious adverse reaction is expected or unexpected for expedited reporting, so its wording has direct regulatory consequences. Ambiguity here creates SUSAR classification disputes with authorities; we write the RSI to be usable as the assessment tool it legally is.
• Synthesis, not accumulation. Annual updates that bolt each year's data onto the last produce documents nobody reads. We re-synthesize, so the guidance to investigators reflects the totality of evidence rather than its chronology.
• Benefit-risk for a clinical audience. The summary of data and guidance for the investigator is where the IB earns its keep: practical dosing guidance, monitoring recommendations, and management of identified risks written for the clinician at the site.
• Consistency with the ecosystem. The IB must agree with the protocol, the DSUR, and the developing safety profile; we cross-check against the documents in our protocol writing and aggregate safety report work so the program tells one story.

Deliverables

Full IB authorship, annual and ad hoc updates, RSI reviews, and remediation of legacy brochures, each with clean version control, tracked scientific rationale for changes, and clinician review throughout, within our broader regulatory medical writing services.